Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis

Elpida Vounzoulaki,1,2 Kamlesh Khunti,1,2 Sophia C Abner,1,2 Bee K Tan,1 Melanie J Davies,1 Clare L Gillies1,2

Objective
To estimate and compare progression rates to type 2 diabetes mellitus (T2DM) in women with gestational diabetes mellitus (GDM) and healthy controls.

Design
Systematic review and meta-analysis.

Data sources
Medline and Embase between January 2000 and December 2019, studies published in English and conducted on humans.

Eligibility criteria for selecting studies
Observational studies investigating progression to T2DM. Inclusion criteria were postpartum follow-up for at least 12 months, incident physician based diagnosis of diabetes, T2DM reported as a separate outcome rather than combined with impaired fasting glucose or impaired glucose tolerance, and studies with both a group of patients with GDM and a control group.

Results
This meta-analysis of 20 studies assessed a total of 956 women with GDM and 373 controls. Data were pooled by random effects meta-analysis models, and heterogeneity was assessed by use of the I² statistic. The pooled relative risk for the incidence of T2DM between participants with GDM and controls was estimated. Reasons for heterogeneity between studies were investigated by prespecified subgroup and meta-regression analyses. Publication bias was assessed by funnel plots and, overall, studies were deemed to have a low risk of bias (P=0.58 and P=0.90). The overall relative risk for T2DM was almost 10 times higher in women with previous GDM than in healthy controls (9.51, 95% confidence interval 7.14 to 12.67, P<0.001). In populations of women with previous GDM, the cumulative incidence of T2DM was 16.46% (95% confidence interval 16.16% to 16.77%) in women of mixed ethnicity, 15.58% (13.30% to 17.86%) in a predominantly non-white population, and 9.91% (9.39% to 10.42%) in a white population. These differences were not statistically significant between subgroups (white v non-white populations, P=0.26; white v mixed populations, P=0.54).

Conclusions
Women with a history of GDM appear to have a nearly 10-fold higher risk of developing T2DM than those with a normoglycaemic pregnancy. This magnitude of risk highlights the importance of intervening to prevent the onset of T2DM, particularly in the early years after pregnancy.

Systematic review registration
PROSPERO CRD42019123079.

Introduction
Gestational diabetes mellitus (GDM) is glucose intolerance with onset or first diagnosis during the second or third trimester of pregnancy, which is clearly not either pre-existing type 1 or type 2 diabetes mellitus (T2DM). A previous diagnosis of GDM is an established risk factor for developing T2DM in later life, a fact that highlights the importance of postpartum screening to identify those at higher risk of progression and introduce strategies for disease prevention. Despite the magnitude of the risk, attendance for postpartum screening is suboptimal, as reported by studies from European countries, the United States, and Canada. An overall lack of awareness of the need for screening and the increased risk for future T2DM in this patient group is apparent. Healthcare providers lack familiarity with, and adherence to, guidelines, and are uncertain as to whether the responsibility for screening these women lies with primary or secondary care. Meanwhile, the prevalence of T2DM is rising globally, with individuals diagnosed with the disease being at higher risk of all cause mortality. Previous systematic reviews have highlighted the increased risk of developing T2DM after GDM. Kim et al, in 2002, identified a cumulative incidence of T2DM of between 2.6% to over 70% in studies with a total follow-up ranging from six weeks to 28 years; this incidence was highest in the first five years after pregnancy. The cumulative incidence of T2DM in women with a known history of GDM has since been calculated as 10% in the study by Szabo et al, conducted on 12 years follow-up.
postpartum years. In 2009, Bellamy et al showed a sevenfold higher risk of T2DM in patients with GDM in comparison with healthy controls (relative risk 7.43, 95% confidence interval 4.79 to 11.51). A further systematic review evaluated the rate of compliance with screening, and the prevalence of T2DM in Asian women, reporting incidences of between 2.8% and 58% in women with previous GDM.

Over recent decades, the demography of pregnant women has changed, with an increase in the rate of women giving birth at a more advanced age, and obesity rates also rising. Both these factors have led to a rise in the prevalence of GDM, establishing the disease as an imminent concern globally. From a public health perspective, this increased prevalence of GDM could contribute to the rising global health burden of obesity and T2DM. To deal with this problem, research has focused on improving the quality and effectiveness of screening and diagnosis of GDM. In addition to changes in the guidelines for GDM, changes have also occurred in the diagnostic criteria for T2DM, in an effort to identify populations at a higher risk. Thus there is a need to evaluate more recent evidence on the risk of progression to T2DM in women with previous GDM compared with those with a normoglycaemic pregnancy, investigating outcomes in ethnically diverse populations, and over a longer follow-up period. This systematic review and meta-analysis aims to investigate progression rates, and factors that could determine progression to T2DM, in women diagnosed with GDM compared with those with a normoglycaemic pregnancy, using recent evidence and including an assessment of both length of follow-up and ethnicity.

Methods
This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analyses Of Observational Studies in Epidemiology (MOOSE) guidelines (supplementary material). The protocol for this systematic review and meta-analysis is registered at https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=123079.

Search strategy and inclusion criteria
We searched Ovid Medline and Embase for observational studies published between January 2000 and December 2019, choosing 2000 as the start date, after release of the 1999 World Health Organization recommendations for performance of the 75 g oral glucose tolerance test at six weeks and onward after labour. A search strategy was developed with the assistance of a clinical librarian. The strategy included both medical subject headings and free text words covering “gestational diabetes” and “type 2 diabetes” and was restricted to studies published in English and conducted on humans. The full search strategy is provided in the supplementary material. All duplicate records were removed.

Two independent authors (EV and SCA) reviewed the titles and abstracts to identify any relevant studies. Full text reports were then obtained and screened in detail against the following predefined eligibility/inclusion criteria: studies reporting postpartum follow-up for at least 12 months, incident physician based GDM and T2DM diagnosis reported, T2DM incidence reported separately rather than combined with impaired fasting glucose or impaired glucose tolerance, and studies with both a group of patients with GDM and a control group. Cross sectional studies and studies reporting postpartum screening attendance but not T2DM progression were excluded. All reference lists from relevant systematic reviews were hand searched for additional eligible studies.

Risk of bias and study quality
We used the Newcastle-Ottawa scale, a scale proposed by Wells et al and designed to evaluate the quality of non-randomised studies. The version of the scale used for cohort studies consists of three categories: selection, comparability, and outcome. Based on the guidelines of the scale, a cohort study can be awarded a maximum of one star for each numbered item from the selection and outcome categories and a maximum of two stars for the category of comparability. A study can be awarded from zero up to nine stars. As the Newcastle-Ottawa scale does not adequately assess potential confounders in study analyses, further information was extracted on which confounders had been considered by each study. Publication bias was assessed with funnel plots for asymmetry using the Begg’s and Egger’s tests.

Data extraction and statistical analysis
Two authors (EV and SCA) independently undertook data extraction according to The Cochrane Handbook guidelines, and findings were reported according to PRISMA and MOOSE guidance. Any disagreement was settled by consensus among all authors. When more than one study investigated outcomes from the same cohort, the study with information most relevant to the analysis was chosen for inclusion. Ethnic origin was defined as white, non-white, or mixed. Studies reporting a homogeneous population comprising at least 80% of the same ethnicity were categorised as white or non-white, and studies reporting a population comprising a number of different ethnicities were categorised as mixed. If ethnicity was not reported, it was defined on the basis of the predominant ethnicity of the country in which the study was conducted. When progression to T2DM was reported at a number of time points, the results from the longest follow-up point were used in the analysis.
To pool study results, random effects meta-analysis models were fitted in Stata 15.1 using the DerSimonian and Laird method, study standard errors were estimated for the log transformed relative risk, and study results were pooled on the log scale. In studies in which T2DM did not occur in any of the groups, we applied a continuity correction using the default value of 0.5 to avoid any division by zero. Any additional parameters were assessed by prespecified subgroup (categorical variables) or meta-regression (continuous variables) analysis.

To further explore the effect of ethnicity and length of follow-up, the risk of T2DM in women with and without GDM was separated, for each study; results were then pooled using random effects meta-analysis models. Subgroup analyses by study level ethnicity, length of study follow-up, study design, and screening method used in pregnancy to diagnose GDM (one step vs two step) were undertaken to investigate sources of heterogeneity between studies. Meta-regression models were also fitted to estimate the effect of study heterogeneity and investigated the cumulative risk of T2DM by age, body mass index, publication year, and length of follow-up. A sensitivity analysis was undertaken to explore the effect of each individual study on the overall pooled estimate.

Patient and public involvement
Patient and public involvement sessions involving women affected by GDM are run regularly at the Diabetes Research Centre to inform our research. In addition, two of the study authors (KK and BKT) have been actively involved with primary care and women’s health for many years and maintain strong community links. Both authors assisted in decisions on outcomes to be considered, protocol development, approach to analysis, and interpretation of the results, to ensure consideration was given to patient and public perspective. As this study was a systematic review and meta-analysis, patient recruitment or use of patient data was not required.

Results
Identified studies
Our initial searches yielded 7448 studies, of which 287 were selected for further evaluation using the full text (fig 1). Of these, 119 were conference proceedings, 72 did not explore outcomes in a group with GDM and a healthy control group, 24 reported postpartum follow-up for a period shorter than 12 months, 15 were not relevant to the research question, 6 did not report the incidence of T2DM, 10 were cross sectional studies, 8 included patients with a self-reported diagnosis of diabetes (either GDM or T2DM or both), 5 were letters and commentaries, 2 were systematic reviews, 2 reported screening in patients already diagnosed with impaired glucose tolerance after GDM, 1 did not compare patients with GDM with a healthy population, and 1 reported information about screening but not progression. Tehrani et al and Hakkarainen et al assessed the same cohorts as Minooee et al and Huopio et al, respectively. We included the last two studies because these reported the most relevant data for the meta-analysis. Retnakaran et al, Feig et al, and Mukerji et al also assessed populations from the same database. From these three, Mukerji et al was included as this study assessed the largest cohort. One study, did not report the necessary data on the incidence of T2DM, and as these could not be obtained from the author, it was not included in the analysis. Finally, three studies retrieved from the reference lists of previous relevant systematic reviews were also included. A total of 20 studies matched all the eligibility criteria.

Study characteristics
The 20 studies included in this systematic review and meta-analysis had differing lengths of follow-up, time of screening, ethnic origin of study participants, and diagnostic criteria for both GDM and T2DM.

All studies were observational, seven were described as prospective cohorts, six as retrospective cohorts, four as population based studies, two as follow-up studies, and one as a hospital based study. Most of these studies were conducted in several European countries, but studies were also from South Asia, the Middle East, the US, Australia, Canada, and Korea. Total postpartum follow-up ranged from one to 25 years. A summary of study characteristics is presented in table 1 with added definitions in box 1.

Study quality
Overall, all included studies that underwent quality assessment with the use of Newcastle-Ottawa scale received a total of six to eight stars, and were thus deemed to have a low risk of bias, using a cut-off point reported in previous reviews using the same tool. One study received a total of five stars, indicating high risk of bias. Studies were adjusted for a variety of different confounders, of which the most common were maternal age, body mass index, family history of T2DM, parity, ethnicity, and socioeconomic status. A summary of the study quality assessment and a separate table showing all study confounders considered when assessing comparability are provided in supplementary tables S1 and S2.

Meta-analysis
In this meta-analysis assessing a total of 1332373 individuals (67956 women with GDM and 1264417 controls), the pooled relative risk for T2DM was almost 10 times higher in women with previous GDM than in healthy controls (relative risk 9.51, 95% confidence interval 7.14 to 12.67, P<0.001). Every study showed that the risk for T2DM was greater in women with GDM than in controls (fig 2).

Significant heterogeneity was seen in the overall effect estimate (I²=96.5%, P<0.001), and hence prespecified subgroup analyses were performed to explore potential sources. The risk for T2DM was
assessed by subgroup analysis for white, non-white, and mixed ethnicity as described by the studies. As shown in figure 3, the pooled relative risk for T2DM in studies with predominantly white populations was 16.28 (95% confidence interval 15.01 to 17.66), non-white 10.38 (4.61 to 23.39), and mixed populations 8.31 (5.44 to 12.69). These relative risks were not statistically significantly different between subgroups (white v mixed, P=0.26 and white v non-white, P=0.54).

The relative risk of T2DM was also assessed by subgroup analysis based on study length of follow-up. As shown in figure 4, studies were separated by their length of follow-up into three groups. The estimated pooled relative risk was 17.06 (95% confidence interval 8.95 to 32.55) for studies with follow-up of one to five years, 10.42 (5.68 to 19.11) for those with follow-up of more than five years and up to 10 years, and 8.09 (4.34 to 15.08) for those with follow-up of more than 10 years. The differences in pooled relative risks by subgroup were not statistically significant (1-5 years v >5-10 years, P=0.63; 1-5 years v >10 years, P=0.38). Although differences were not statistically significant, the relative risk of T2DM in women with GDM compared with controls seemed to be higher in the shorter studies (<5 years; fig 4).

For a better understanding of why relative risks might have varied by ethnicity and length of follow-up, the estimated cumulative incidences for both women who had had GDM, and healthy controls were calculated for each study and pooled by subgroup (table 2). The cumulative incidence of T2DM was found to be higher in a population with a mix of ethnicities or a non-white population than in white populations, for both women who had had GDM, and healthy controls. These results were not statistically significant (table 2), however, and could partially be explained by the longer follow-up in studies assessing mixed ethnicities.
For length of study follow-up, in women with GDM the pooled cumulative incidence was estimated to be around 9.22% (95% confidence interval 7.19% to 11.26%) in studies with one to five years of follow-up, increasing to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative incidence in controls reached 1.90% (95% confidence interval 1.87% to 1.92%) for the longest studies. The cumulative incidence in controls increased to 16.15% (15.83% to 16.47%) for studies with more than 10 years of follow-up. The cumulative inc...
Box 1: Type 2 diabetes mellitus and gestational diabetes mellitus criteria as used in Table 1

**Criteria for gestational diabetes mellitus (GDM)**
- ADA (2004)—two or more raised values during oral glucose tolerance test: fasting plasma glucose ≥95 mg/dL (5.3 mmol/L), one hour glucose ≥180 mg/dL (10.0 mmol/L), two hour glucose ≥155 mg/dL (8.6 mmol/L), three hour glucose ≥140 mg/dL (7.8 mmol/L) after 100 g oral glucose tolerance test
- ADIPS (1999)—fasting plasma glucose ≥5.5 mmol/L or two hour glucose ≥8.0 mmol/L after 75 g oral glucose tolerance test
- Carpenter and Coustan—two or more raised values during oral glucose tolerance test: fasting plasma glucose ≥95 mg/dL (5.3 mmol/L), one hour glucose ≥180 mg/dL (10.0 mmol/L), two hour glucose ≥155 mg/dL (8.6 mmol/L), three hour glucose ≥140 mg/dL (7.8 mmol/L) after 100 g oral glucose tolerance test
- Contemporary criteria—one or more raised values during oral glucose tolerance test: fasting plasma glucose ≥4.8 mmol/L, one hour glucose ≥10.0 mmol/L, two hour glucose ≥8.7 mmol/L until September 2001; since September 2001 fasting plasma glucose ≥4.8 mmol/L, one hour glucose ≥11.2 mmol/L, two hour glucose ≥9.9 mmol/L after 75 g oral glucose tolerance test
- EASD—two hour glucose ≥9 mmol/L after 75 g oral glucose tolerance test
- IADPSG—fasting plasma glucose ≥92 mg/dL (5.1 mmol/L), one hour glucose ≥180 mg/dL (10.0 mmol/L), two hour glucose ≥153 mg/dL (8.5 mmol/L) after 75 g oral glucose tolerance test
- NICE—patients were classified as having GDM or T2DM based on clinical codes used in the Health Improvement Network database that were based on the classification made by NICE 2008 and 2015 guidelines for diabetes in pregnancy:
  - NICE 2008—fasting plasma glucose ≥7.0 mmol/L or two hour glucose ≥7.8 mmol/L after 75 g oral glucose tolerance test
  - NICE 2015—fasting plasma glucose ≥5.6 mmol/L or two hour glucose ≥7.8 mmol/L after 75 g oral glucose tolerance test
- NDDG (1979)—fasting plasma glucose ≥105 mg/dL (5.8 mmol/L), one hour glucose ≥190 mg/dL (10.6 mmol/L), two hour glucose ≥165 mg/dL (9.2 mmol/L), three hour glucose ≥145 mg/dL (8.0 mmol/L) after 100 g oral glucose tolerance test
- Second and third workshop conference on GDM—two or more raised values during oral glucose tolerance test: fasting plasma glucose ≥5.8 mmol/L, one hour glucose ≥10.6 mmol/L, two hour glucose ≥9.2 mmol/L, three hour glucose ≥8.1 mmol/L after 100 g oral glucose tolerance test
- WHO (1985)—fasting plasma glucose ≥7.0 mmol/L or two hour glucose ≥11.1 mmol/L after 75 g oral glucose tolerance test
- WHO (1999)—fasting plasma glucose ≥7.0 mmol/L, two hour glucose ≥7.8 mmol/L after 75 g oral glucose tolerance test

**Criteria for type 2 diabetes mellitus (T2DM)**
- ADA (1997)—fasting plasma glucose ≥7.0 mmol/L or two hour glucose ≥11.1 mmol/L after 75 g oral glucose tolerance test
- CDA (2008)—fasting plasma glucose ≥7.0 mmol/L or two hour glucose ≥11.1 mmol/L after 75 g oral glucose tolerance test
- CDA (2013)—fasting plasma glucose ≥7.0 mmol/L or two hour glucose ≥11.1 mmol/L or HbA1c ≥6.5% (48 mmol/mol)
- Local criteria—HbA1c ≥7.25% (55.7 mmol/mol) or glucose ≥11.1 mmol/L
- NICE: patients were classified as having GDM or T2DM based on clinical codes used in the Health Improvement Network database that were based on the classification made by the NICE 2008 and 2015 guidelines for diabetes in pregnancy:
  - NICE 2008—fasting plasma glucose ≥7.0 mmol/L, two hour glucose ≥11.1 mmol/L, diagnosis with the 75 g oral glucose tolerance test
  - NICE 2015—fasting plasma glucose ≥7.0 mmol/L (receive further testing to confirm T2DM), HbA1c ≥6.5% (48.0 mmol/mol)
- WHO (1985)—fasting plasma glucose ≥7.8 mmol/L or two hour glucose ≥11.1 mmol/L after 75 g oral glucose tolerance test
- WHO (1998)—fasting plasma glucose ≥7.0 mmol/L, two hour glucose ≥11.1 mmol/L after 75 g oral glucose tolerance test

No indication of publication bias was found, with both Begg’s and Egger’s tests being statistically non-significant (P=0.58 and P=0.90, respectively). The funnel plot of the 20 studies included in the meta-analysis is provided in supplementary figure S4.

**Discussion**

**Principal findings**

The results of this systematic review and meta-analysis suggest that women with a history of GDM are almost 10 times more likely to develop T2DM than those with a normoglycaemic pregnancy. The magnitude of this risk is consistent with evidence that the two conditions share common pathogenic mechanisms and risk factors, suggesting that GDM could potentially serve as a predictor for future development of T2DM.

**Strengths and limitations**

Among the strengths of this study are the substantial number of recently published studies, assessing a large total number of individuals, and with long term follow-up, ranging from one to 25 years. Guidelines for the screening, diagnosis, and follow-up care for women with GDM have changed in a number of countries over the past decade, while the overall prevalence of T2DM has increased. This review provides up-to-date results in contemporary populations.

Nevertheless, this study had several limitations. Owing to limited resources, we had to exclude studies not published in English. Furthermore, owing to a lack of information on family history of diabetes or parity, we were not able to examine the potential effect of these factors on the incidence of T2DM. Additionally, while several primary studies adequately reported the ethnicity of study participants, others provided little or no information and had to be grouped using broad ethnic categories. Thus, we could not investigate progression in ethnic subgroups, which could have been a cause of heterogeneity between studies. The subsequent risk of T2DM in both women with previous GDM and healthy controls was estimated using relative risks, as person years of follow-up were not reported for every study. Thus we were not able to calculate incidence rate ratios consistently across studies. A further limitation was that although we assessed the cumulative incidence by study length of follow-up, it...
was difficult to reach conclusions about the timing of T2DM onset using study level data, as the cumulative incidence was known only at the end of the study and not when the events occurred. A more accurate assessment of cumulative incidence would require individual patient data, in a cohort where regular screening took place. In addition, the prespecified meta-regression analyses carried out to assess heterogeneity between studies lack power to identify associations between variables, as they are limited to the use of study level data. Overall, we were unable to identify the main sources of heterogeneity in our effect estimates, and a more in-depth analysis could have been performed if individual patient level data had been available.

To assess the quality of our included studies, we used the Newcastle-Ottawa scale. The validity of this scale has been questioned by previous studies, because it gives little attention to study confounders.²² Although the Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) has been suggested as a high quality, validated scale,⁵³ we were not able to use it for this meta-analysis, because our primary studies did not involve any interventions. To deal with this problem, we carefully evaluated potential confounders in primary studies, and listed them thoroughly. Most of the studies included were at low risk of bias, with only one study⁵⁵ potentially at high risk of bias. The funnel plot and statistical tests performed showed no evidence of publication bias in our meta-analysis.

Comparison with other studies
Our findings are similar to results from previously published systematic reviews, suggesting a higher incidence of T2DM in women with GDM than in those unaffected, with the overall 95% confidence interval obtained by Bellamy et al overlapping with the one we identified.¹² ¹³ In this systematic review and meta-analysis, we incorporated evidence from the most recent studies and identified a higher estimated risk of T2DM than found previously.

Kim et al and Bellamy et al assessed studies published between 1965 and 2001 and between 1960 and 2009, respectively.¹² ¹³ As screening criteria have changed, with the cut-off level of fasting plasma glucose for T2DM being lowered from 7.8 to 7.0 mmol/L in 1997,⁵⁴ this could have led to an underestimation of the overall risk of subsequent T2DM in women with previous GDM. Some of our included studies, however, involved both women diagnosed with the criteria used before 1997, and women diagnosed with the revised criteria.¹¹ ¹４ ¹５ ¹６ ¹７ ¹８ ¹⁹ ¹０ Additionally, previous systematic reviews have focused on a specific ethnic group,¹⁴ or included studies with short term follow-up (≤6 months).¹² ¹⁶ Kim et al also showed a higher cumulative incidence of T2DM in the first five
postpartum years, which then seemed to plateau in further years. This cumulative incidence of T2DM was seen to increase steadily over time, with the highest incidence being seen in those studies with the longest follow-up.

This analysis did not show a statistically significant difference in the relative risk of T2DM in different ethnic groups. This result could be due to a lack of power to detect any potential differences, consistent with previous research showing that after adjusting for covariates, progression to T2DM between different ethnic groups seemed similar in all women with previous GDM. Similarly, Bellamy et al found no difference in the overall relative risk between the different ethnic groups of the included studies.

Implications for research and clinical practice

The substantially higher risk of subsequent progression to T2DM in women diagnosed with GDM identified in this systematic review is perhaps not surprising, considering the poor postpartum screening uptake in this population, and lack of structured postpartum preventive care. Some of the barriers highlighted by previous research include poor communication between clinicians and patients, and between healthcare professionals in primary and secondary care, lack of awareness of T2DM risk due to poor patient education, and time restrictions due to maternal duties. Our results could increase awareness in patients of the need to attend postpartum screening, and in healthcare professionals of the need to use patient centred strategies to improve screening uptake. Future research could further investigate the timing of onset of T2DM in these populations, using individual patient data, to provide a more accurate estimate of time.

The long term health benefits associated with the adoption of lifestyle and pharmacological interventions aimed at preventing the onset of T2DM in women with GDM have been well recognised. Nevertheless, more up-to-date large randomised controlled trials are needed to investigate the effectiveness of those interventions in ethnically diverse populations, and with longer follow-up, to support the generalisability and external validity of these results. Finally, the cost effectiveness of these interventions should be considered to promote their adoption by different healthcare systems across the world.
Conclusions

In summary, women with a history of GDM have a nearly 10-fold increased risk of developing T2DM, in comparison with those with a normoglycaemic pregnancy. These high rates of progression suggest an urgent need to promote postpartum screening among these women and to encourage them to adopt dietary, lifestyle, and pharmacological interventions to prevent or delay the onset of T2DM. Future studies should examine strategies to improve screening uptake and evaluate the effectiveness and cost effectiveness of preventive interventions, across heterogeneous populations and over long periods.

Contributors: EV, KK, and CLG conceived the idea of the study; EV and SCA screened the studies and undertook data extraction; EV carried out the statistical analysis, CLG supervised the analysis. EV, CLG, KK, BKT, and MJD interpreted the findings; and EV drafted the manuscript. CLG, KK, MJD, and BKT critically reviewed the manuscript and EV revised the manuscript for final submission. All authors have approved the final draft of the manuscript. EV is guarantor. EV accepts full

---

**Table 2** | Cumulative incidence of type 2 diabetes by ethnicity and length of follow-up in separate groups

<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>No of contributing studies</th>
<th>Study length (years; mean (range))</th>
<th>GDM (%; 95% CI)</th>
<th>Controls (%; 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>6</td>
<td>7.28 (1.00-15.00)</td>
<td>9.91 (9.39 to 10.42)</td>
<td>0.61 (0.58 to 0.65)</td>
</tr>
<tr>
<td>Mixed</td>
<td>10</td>
<td>11.44 (1.00-25.00)</td>
<td>16.46 (16.16 to 16.77)</td>
<td>1.91 (1.88 to 1.93)</td>
</tr>
<tr>
<td>Non-white</td>
<td>4</td>
<td>6.00 (2.00-10.00)</td>
<td>15.58 (13.30 to 17.86)</td>
<td>2.02 (1.35 to 2.69)</td>
</tr>
<tr>
<td>Study follow-up length (years):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-5</td>
<td>6</td>
<td>2.83 (1.00-5.00)</td>
<td>9.22 (7.19 to 11.26)</td>
<td>1.19 (0.46 to 1.93)</td>
</tr>
<tr>
<td>&gt;5-10</td>
<td>7</td>
<td>7.61 (5.40-10.00)</td>
<td>12.06 (11.59 to 12.53)</td>
<td>0.69 (0.66 to 0.73)</td>
</tr>
<tr>
<td>&gt;10</td>
<td>7</td>
<td>15.97 (11.00-25.00)</td>
<td>16.15 (15.83 to 16.67)</td>
<td>1.90 (1.87 to 1.92)</td>
</tr>
</tbody>
</table>

---

**Table 3** | Results of meta-regression models

<table>
<thead>
<tr>
<th>Study level variables</th>
<th>Coefficient (95% CI)</th>
<th>P value</th>
<th>I² (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean)</td>
<td>1.02 (0.93 to 1.12)</td>
<td>0.67</td>
<td>96.00</td>
</tr>
<tr>
<td>Body mass index (mean)</td>
<td>0.97 (0.87 to 1.08)</td>
<td>0.52</td>
<td>80.43</td>
</tr>
<tr>
<td>Publication year</td>
<td>1.01 (0.92 to 1.10)</td>
<td>0.87</td>
<td>96.66</td>
</tr>
<tr>
<td>Length of follow-up (mean)</td>
<td>1.00 (0.93 to 1.07)</td>
<td>0.94</td>
<td>96.67</td>
</tr>
</tbody>
</table>

---

**Fig 4** | Relative risk of type 2 diabetes mellitus (T2DM) in women with gestational diabetes mellitus (GDM) and controls based on study length of follow-up

---

**Table 3** | Results of meta-regression models
responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish. The corresponding author attests that all listed authors meet authorship criteria and that no other meetings the criteria have been omitted.

Funding: This report is the independent research of EV, supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands and NIHR Leicester Biomedical Research Centre for the submitted work. KK has acted as a consultant and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Server, and Merck Sharp and Dohe; has received grants in support of investigator and investigator initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim, Merck Sharp and Dohe, and has received funds for research; for speaking at meetings and has served on advisory boards for Lilly, Sanofi-Aventis, Merck Sharp and Dohe, and Novo Nordisk. MD has acted as consultant, advisory board member and speaker for Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp and Dohe, Boehringer Ingelheim, AstraZeneca, and Janssen; as a speaker for Mitsubishi Tanabe Pharma Corporation; and has received grants in support of investigator and investigator initiated trials from Novo Nordisk, Sanofi-Aventis, and Lilly. All other authors declare no competing interests, or activities that could appear to have influenced the submitted work.

Ethical approval: Ethical approval was not required.

Data sharing: Data are available upon reasonable request. Technical appendix, statistical code, and dataset available from the corresponding author at ev63@le.ac.uk.

The lead author (EV) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Dissemination to participants and related patient and public communities: The results of this study will be disseminated to the Royal College of General Practitioners and the diabetes prevention programme committee, of which KK is a member. The authors will additionally issue a press release in collaboration with the BMJ. These results will also be disseminated to national and international diabetes conferences. Where possible, results of this systematic review and meta-analysis will be disseminated to the patient community and to regional and national committees through the study authors.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.


10 Seidu S, Khunti K. Non-adherence to diabetes guidelines in primary care - a collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from the NIHR Applied Research Collaboration East Midlands and NIHR Leicester Biomedical Research Centre for the submitted work. KK has acted as a consultant and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Server, and Merck Sharp and Dohe; has received grants in support of investigator and investigator initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim, and has received funds for research; for speaking at meetings and has served on advisory boards for Lilly, Sanofi-Aventis, Merck Sharp and Dohe, and Novo Nordisk. MD has acted as consultant, advisory board member and speaker for Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp and Dohe, Boehringer Ingelheim, AstraZeneca, and Janssen; as a speaker for Mitsubishi Tanabe Pharma Corporation; and has received grants in support of investigator and investigator initiated trials from Novo Nordisk, Sanofi-Aventis, and Lilly. All other authors declare no competing interests, or activities that could appear to have influenced the submitted work.

11 Ethical approval: Ethical approval was not required.

Data sharing: Data are available upon reasonable request. Technical appendix, statistical code, and dataset available from the corresponding author at ev63@le.ac.uk.

The lead author (EV) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Dissemination to participants and related patient and public communities: The results of this study will be disseminated to the Royal College of General Practitioners and the diabetes prevention programme committee, of which KK is a member. The authors will additionally issue a press release in collaboration with the BMJ. These findings will inform the Baby Steps study run by the Diabetes Research Centre, which aims to implement a structured group education programme for women with a history of gestational diabetes. Finally, results will also be disseminated to national and international diabetes conferences. Where possible, results of this systematic review and meta-analysis will be disseminated to the patient community and to regional and national committees through the study authors.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.


**Web appendix:** Supplementary material